These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34680346)

  • 1. PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients.
    Battaglia A; Piermattei A; Buzzonetti A; Pasciuto T; Zampetti N; Fossati M; Angelico G; Iacobelli V; Nero C; Iannucci V; Scambia G; Fagotti A; Fattorossi A
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
    Fanale D; Corsini LR; Brando C; Cutaia S; Di Donna MC; Filorizzo C; Lisanti MC; Randazzo U; Magrin L; Romano R; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Chiantera V; Russo A; Bazan V; Iovanna JL
    Front Oncol; 2022; 12():946319. PubMed ID: 36212445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer.
    Del Re M; Vivaldi C; Rofi E; Salani F; Crucitta S; Catanese S; Fontanelli L; Massa V; Cucchiara F; Fornaro L; Capuano A; Fogli S; Vasile E; Danesi R
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.
    Asante DB; Morici M; Mohan GRKA; Acheampong E; Spencer I; Lin W; van Miert P; Gibson S; Beasley AB; Ziman M; Calapre L; Meniawy TM; Gray ES
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gottlieb CE; Mills AM; Cross JV; Ring KL
    Gynecol Oncol; 2017 Mar; 144(3):607-612. PubMed ID: 28065619
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Wieser V; Gaugg I; Fleischer M; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Zeimet AG; Fiegl H; Marth C
    Oncotarget; 2018 Apr; 9(25):17501-17511. PubMed ID: 29707124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvesicles in plasma reflect coronary flow reserve in patients with cardiovascular disease.
    Bryl-Górecka P; James K; Torngren K; Haraldsson I; Gan LM; Svedlund S; Olde B; Laurell T; Omerovic E; Erlinge D
    Am J Physiol Heart Circ Physiol; 2021 May; 320(5):H2147-H2160. PubMed ID: 33797274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
    Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
    J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
    Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
    Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enumeration and phenotyping of circulating microvesicles by flow cytometry and nanoparticle tracking analysis: Plasma versus serum.
    Siwaponanan P; Keawvichit R; Lekmanee K; Chomanee N; Pattanapanyasat K
    Int J Lab Hematol; 2021 Jun; 43(3):506-514. PubMed ID: 33244869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling.
    Mokarizadeh A; Delirezh N; Morshedi A; Mosayebi G; Farshid AA; Mardani K
    Immunol Lett; 2012 Sep; 147(1-2):47-54. PubMed ID: 22705267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
    Raimondi L; Raimondi FM; Di Benedetto L; Cimino G; Spinelli GP
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.